| abstract |
The present disclosure relates to a heterocyclic compound represented by the general formula I, pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers thereof , racemates, polymorphs, solvates or isotopically-labeled compounds, pharmaceutical compositions comprising the heterocyclic compounds, and pharmaceutical uses thereof. The heterocyclic compounds of the present disclosure are a class of immunomodulators, in particular, immunomodulators involving a class of compounds that activate STING. |